Study on Pirtobrutinib for Patients with Previously Treated Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
Sponsor: Eli Lilly and Company
Sponsor score: 60
ClinicalTrials ID:NCT06876662
This study is for patients who have already participated in a previous trial and are continuing their treatment or follow-up. It aims to assess the long-term safety and effectiveness of the drug Pirtobrutinib for those with Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Patient Parameters
| Parameter | Options |
|---|
Program Overview
This study is a continuation for participants from a previous trial who are either still receiving treatment or are in follow-up stages. It focuses on evaluating how safe and effective Pirtobrutinib is over a longer period for patients with Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.
Eligibility Criteria
Inclusion Criteria
- Currently participating in the original study (18001) and are:
- Receiving treatment
- In short-term follow-up
- In long-term follow-up
Exclusion Criteria
- Participated in the Phase 1b part of Study 18001.
- Are pregnant or planning to become pregnant during the study or within 30 days after the last dose.
- Intend to breastfeed during the study or within 1 week after the last dose.
Locations
| FACILITY | ZIP | CITY | STATE |
|---|---|---|---|
| Sylvester Comprehensive Cancer Center | 33136-1002 | Miami | Florida |
| Florida Cancer Specialists | 34232-6422 | Sarasota | Florida |
| The Emory Clinic | 30322-1013 | Atlanta | Georgia |
| Northwestern University | 60611-3013 | Chicago | Illinois |
| Dana-Farber Cancer Institute | 02115 | Boston | Massachusetts |
| Mayo Clinic- Minnesota | 55905 | Rochester | Minnesota |
| University Of Nebraska Medical Center | 69198 | Omaha | Nebraska |
| Northwell Health | 11042-1118 | Lake Success | New York |
| Memorial Sloan-Kettering Cancer Center (MSKCC) - New York | 10065-6007 | New York | New York |
| Duke University Medical Center | 27710-4000 | Durham | North Carolina |
Get This Program In Your Inbox
Receive detailed information about this treatment opportunity to review with your healthcare provider.